Abstract

ASSESSMENT OF EFFECTIVENESS OF REMDESIVIR IN COVID 19 PATIENTS ADMITTED IN A TERTIARY CARE UNIT

Gayathri Prabhakumar*, Aparna S., Shiraz S., Kavitha K.V. and Safna N Fazil

ABSTRACT

Aim and objectives: The study aims to assess the effectiveness of Remdesivir in COVID-19 patients admitted to a tertiary care hospital. Materials and methods: This is a prospective cross- sectional study of Intravenous Remdesivir in adults hospitalized with COVID-19 with evidence of lower respiratory tract involvement. The study was done for a period of 6 months involving 64 patients diagnosed with COVID-19. Patients were randomly assigned to receive either Remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 4 additional days) or placebo for up to 5 days. The primary endpoint was time to clinical improvement up to day 28, defined as the time (in days) from randomization to the point of a decline of two levels on a six-point ordinal scale of clinical status (from 1=discharged to 6=death). The post COVID-19 complication was also assessed. Results: Among 64 patients, males (62.50%) are more prevalent. It can be observed that majority of the respondents (57.81 %) belong to‗ ≥ 60‘ Age Group. Majority of the respondents (60.94 %) are affected by ‗Diabetes mellitus‘. Majority of the respondents were affected with Pneumonia (36%) as a post COVID-19 complication. Results from 64 patients (40 assigned to Remdesivir and 23 assigned to placebo), Patients receiving Remdesivir had a numerically faster time to clinical improvement than those receiving placebo. The mean value for TTCI between groups within Remdesivir administration for 7, 14 days are 2.615, 4.600 compared with 3.737, 6.250 of placebo group. Conclusion: This study suggests that Remdesivir was associated with a significant decrease in the time to clinical recovery among patients admitted to the hospital for treatment of COVID19 when compared to patients under standard care.

Keywords: COVID-19, TTCI, Diabetes Mellitus, Remdesivir, Placebo.